Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

Diabetes and Metabolism

Volumn 45, Issue 5, 2019, Pages 409-418

  Aroda, V R ^a   Ahmann, A ^b   Cariou, B ^c   Chow, F ^d   Davies, M J ^e   Jodar E ^f   Mehta, R ^g   Woo, V ^h   Lingvay, I ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c L INSTITUT DU THORAX   (France)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f Universidad Europea de Madrid Centro Nacional de Investigaciones Cardiovasculares Carlos III   (Spain)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cardiovascular; Efficacy; Glucagon like peptide 1 receptor agonist; Semaglutide, SUSTAIN; Type 2 diabetes

Indexed keywords

DULAGLUTIDE; EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; LIPID; PLACEBO; SEMAGLUTIDE; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN;

BLOOD PRESSURE; BODY WEIGHT; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; VOMITING; WAIST CIRCUMFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, SUBCUTANEOUS; TREATMENT OUTCOME;

EID: 85065773014     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2018.12.001     Document Type: Review

References (59)

1. American Diabetes Association. Standards of Medical Care in Diabetes-2018. Diabetes Care 41:Suppl 1 (2018), S1–S135.
2. Khunti, K, Ceriello, A, Cos, X, De Block, C, Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 137 (2018), 137–148.
3. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/02/WC500243464.pdf; 2018 [accessed 31 May 2018].
4. Menke A, Knowler WC, Cowie CC. Physical and metabolic characteristics of persons with diabetes and prediabetes. Chapter 9. In: Diabetes in America, 3rd ed. Cowie CC, et al. Eds. Bethesda: MD, National Institutes of Health; 2017: 9–14.
5. Franz, MJ, Boucher, JL, Rutten-Ramos, S, VanWormer, JJ., Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 115 (2015), 1447–1463.
6. Wing, RR, Espeland, MA, Clark, JM, Hazuda, HP, Knowler, WC, Pownall, HJ, et al. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care 39 (2016), 1345–1355.
7. Haffner, SM, Lehto, S, Ronnemaa, T, Pyorala, K, Laakso, M, Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998), 229–234.
8. Booth, GL, Kapral, MK, Fung, K, Tu, JV, Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368 (2006), 29–36.
9. Scirica, BM, Bhatt, DL, Braunwald, E, Steg, PG, Davidson, J, Hirshberg, B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
10. Green, JB, Bethel, MA, Armstrong, PW, Buse, JB, Engel, SS, Garg, J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
11. Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
12. Neal, B, Perkovic, V, Mahaffey, KW, de Zeeuw, D, Fulcher, G, Erondu, N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
13. Marso, SP, Daniels, GH, Brown-Frandsen, K, Kristensen, P, Mann, JF, Nauck, MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
14. Marso, SP, Bain, SC, Consoli, A, Eliaschewitz, FG, Jodar, E, Leiter, LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
15. Pfeffer, MA, Claggett, B, Diaz, R, Dickstein, K, Gerstein, HC, Kober, LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
16. Holman, RR, Bethel, MA, Mentz, RJ, Thompson, VP, Lokhnygina, Y, Buse, JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
17. White, WB, Cannon, CP, Heller, SR, Nissen, SE, Bergenstal, RM, Bakris, GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
18. Hernandez, AF, Green, JB, Janmohamed, S, D'Agostino, RB, Granger, CB, Jones, NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
19. Eli Lilly Press Release., https://investor.lilly.com/node/39796/pdf; 2018 [accessed 31 May 2018].
20. Wiviott, SD, Raz, I, Bonaca, MP, Mosenzon, O, Kato, ET, Cahn, A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2018, 10.1056/NEJMoa1812389 [Epub ahead of print].
21. Lee, WL, Cheung, AM, Cape, D, Zinman, B, Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 23 (2000), 962–968.
22. Gaede, P, Vedel, P, Larsen, N, Jensen, GV, Parving, HH, Pedersen, O, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
23. Davies, MJ, D'Alessio, DA, Fradkin, J, Kernan, WN, Mathieu, C, Mingrone, G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 (2018), 2669–2701.
24. Lau, J, Bloch, P, Schaffer, L, Pettersson, I, Spetzler, J, Kofoed, J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58 (2015), 7370–7380.
25. Novo Nordisk A/S. Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes, http://press.novonordisk-us.com/2017-12-5-Novo-Nordisk-Receives-FDA-Approval-of-OZEMPIC-R-semaglutide-Injection-For-the-Treatment-of-Adults-with-Type-2-Diabetes; [accessed Mar 5, 2018].
26. ® (semaglutide) approved in the EU for the treatment of type 2 diabetes, https://www.novonordisk.com/bin/getPDF.2167679. pdf; 2018 [accessed 31 May 2018].
27. ® approved in Canada for the treatment of adults with type 2 diabetes, https://www.newswire.ca/news-releases/ozempic-approved-in-canada-for-the-treatment-of-adults-with-type-2-diabetes-668432133.html; 2018 [accessed 31 May 2018].
28. ® approved in Japan for the treatment of type 2 diabetes, https://www.novonordisk.com/bin/getPDF.2178681.pdf [accessed 31/05/2018].
29. Donath, MY, Burcelin, R, GLP-1 effects on islets: hormonal, neuronal, or paracrine?. Diabetes Care 36:Suppl 2 (2013), S145–S148.
30. Secher, A, Jelsing, J, Baquero, AF, Hecksher-Sorensen, J, Cowley, MA, Dalboge, LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124 (2014), 4473–4488.
31. Blundell, J, Finlayson, G, Axelsen, MB, Flint, A, Gibbons, C, Kvist, T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19 (2017), 1242–1251.
32. Sorli, C, Harashima, SI, Tsoukas, GM, Unger, J, Karsbøl, JD, Hansen, T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5 (2017), 251–260.
33. Ahrén, B, Masmiquel, L, Kumar, H, Sargin, M, Karsbol, JD, Jacobsen, SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5 (2017), 341–354.
34. Ahmann, AJ, Capehorn, M, Charpentier, G, Dotta, F, Henkel, E, Lingvay, I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 41 (2018), 258–266.
35. Aroda, VR, Bain, SC, Cariou, B, Piletic, M, Rose, L, Axelsen, M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5 (2017), 355–366.
36. Rodbard, HW, Lingvay, I, Reed, J, de la Rosa, R, Rose, L, Sugimoto, D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 103 (2018), 2291–2301.
37. Pratley, RE, Aroda, VR, Lingvay, I, Ludemann, J, Andreassen, C, Navarria, A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6 (2018), 275–286.
38. Seaquist, ER, Anderson, J, Childs, B, Cryer, P, Dagogo-Jack, S, Fish, L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36 (2013), 1384–1395.
39. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf; 2008 [accessed 31 May 2018].
40. Rodbard H, Bellary S, Hramiak I, Seino Y, Silver R, Bergan EQ, et al. Responder analysis of subjects achieving HbA1c ≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials. ePoster number 802. Lisbon 2017 EASD, https://www.easd.org/myeasd/home.html#!resources/responder-analysis-of-subjects-achieving-hba-sub-1c-sub-1-and-weight-loss-5-across-sustain-1-5-clinical-trials-86583438-fc4a-46b6-b123-8829251827b1; 2017 [accessed 31 May 2018].
41. Ahrén, B, Atkin, SL, Charpentier, G, Warren, ML, Wilding, JPH, Birch, S, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab 20 (2018), 2210–2219.
42. 1c below 7.0% without weight gain, hypoglycaemia, and gastrointestinal adverse events vs. comparators in the SUSTAIN 1–5 trials., Lisbon, Portugal; 11-15 September European Association for the Study of Diabetes (EASD) – 53rd Annual Meeting, 2017 [Poster 815].
43. 1c subgroups in the SUSTAIN 1–5 clinical trials., San Diego, CA, USA, June 9–13 77th Scientific Sessions of the American Diabetes Association, 2017.
44. Atkin, S, Woo, V, de la Rosa, R, Wilding, J, Yamada, Y, et al. The impact of gastrointestinal adverse events on weight loss with semaglutide in subjects with type 2 diabetes., Lisbon, Portugal; 11-15 September European Association for the Study of Diabetes (EASD) – 53rd Annual Meeting, 2017 [Poster 821].
45. Vilsbøll, T, Bain, SC, Leiter, LA, Lingvay, I, Matthews, D, Simó, R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20 (2018), 889–897.
46. Intarcia Therapeutics press release. Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO Trial for ITCA 650, an investigational therapy for type 2 diabetes, https://www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html [Accessed October, 2017].
47. Zelniker, TA, Wiviott, SD, Raz, I, Im, K, Goodrich, EL, Bonaca, MP, et al. SGLT-2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 2018 [pii: S0140-6736(18)32590-X; Epub ahead of print].
48. Health Canada. OZEMPIC (semaglutide) injection product monograph, Jan 09, 2018, http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/ozempic-product-monograph.pdf; 2018 [accessed 31 May 2018].
49. US Food and Drug Administration. OZEMPIC (semaglutide) injection prescribing information; https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf; 2017 [accessed 31 May 2018.
50. Summary product characteristics Ozempic, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004174/WC500244163.pdf [accessed April 2018].
51. Scheen, AJ, GLP-1 receptor agonists and cardiovascular protection: a class effect or not?. Diabetes Metab 44 (2018), 193–196.
52. Jorsal, A, Kistorp, C, Holmager, P, Tougaard, RS, Nielsen, R, Hanselmann, A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
53. Vilsbøll TG, Gumprecht J, Silver RJ, Hansen T, Pettersson J, Wilding J. Semaglutide treatment and renal function in the SUSTAIN 6 trial. 77th Scientific Sessions of the American Diabetes Association 2018 [Poster 1084-P].
54. Marbury, T, Flint, A, Segel, S, Lindegaard, M, Lasseter, K, Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet 56 (2017), 1381–1390.
55. Trujillo, JM, Nuffer, W, Ellis, SL, GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 6 (2015), 19–28.
56. Warren, M, Chaykin, L, Trachtenbarg, D, Nayak, G, Wijayasinghe, N, Cariou, B, Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. Diabetes Obes Metab 20 (2018), 2291–2297.
57. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
58. Nathan, DM, Genuth, S, Lachin, J, Cleary, P, Crofford, O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
59. Prasad-Reddy, L, Isaacs, D, A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context, 4, 2015, 212283.